The Current Role of Radiation in the Management of Cholangiocarcinoma-A Narrative Review
- PMID: 38730728
- PMCID: PMC11083065
- DOI: 10.3390/cancers16091776
The Current Role of Radiation in the Management of Cholangiocarcinoma-A Narrative Review
Abstract
Cholangiocarcinoma (CCA) is a rare cancer of bile ducts. It is associated with a poor prognosis. The incidence of CCA is rising worldwide. Anatomical subgroups have been used to classify patients for treatment and prognosis. There is a growing understanding of clinically important distinctions based on underlying genetic differences that lead to different treatment options and outcomes. Its management is further complicated by a heterogeneous population and relative rarity, which limits the conduct of large trials to guide management. Surgery has been the primary method of therapy for localized disease; however, recurrence and death remain high with or without surgery. Therefore, there have been concerted efforts to investigate new treatment options, such as the use of neoadjuvant treatments to optimize surgical outcomes, targeted therapy, leveraging a new understanding of immunobiology and stereotactic radiation. In this narrative review, we address the evidence to improve suboptimal outcomes in unresectable CCA with radiation, as well as the role of radiation in neoadjuvant and postoperative treatment. We also briefly discuss the recent developments in systemic treatment with targeted therapies and immune checkpoint inhibitors.
Keywords: chemotherapy; cholangiocarcinoma; gallbladder; radiotherapy; surgery; systemic therapy; targeted treatment.
Conflict of interest statement
DB has accepted honoraria and/or speaking fees from Astra Zeneca, Amgen, Bristol-Myers Squibb, Takeda, Bayer, Guardant, Roche, Janssen, and Merck. ML has accepted honoraria and/or consulting fees from Tersera, Ferring, Eisai, Tolmar, Abbvie, Bayer, and Knight Therapeutics. The rest of the authors have no conflicts of interest.
Figures
Similar articles
-
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.Cancer Treat Res Commun. 2021;27:100354. doi: 10.1016/j.ctarc.2021.100354. Epub 2021 Mar 16. Cancer Treat Res Commun. 2021. PMID: 33756174 Review.
-
Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs.Expert Opin Pharmacother. 2022 Mar;23(4):473-481. doi: 10.1080/14656566.2021.2020250. Epub 2021 Dec 29. Expert Opin Pharmacother. 2022. PMID: 34964678 Review.
-
Clinical treatment of cholangiocarcinoma: an updated comprehensive review.Ann Hepatol. 2022 Sep-Oct;27(5):100737. doi: 10.1016/j.aohep.2022.100737. Epub 2022 Jul 7. Ann Hepatol. 2022. PMID: 35809836 Review.
-
Future directions in the treatment of cholangiocarcinoma.Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):355-61. doi: 10.1016/j.bpg.2015.02.010. Epub 2015 Feb 19. Best Pract Res Clin Gastroenterol. 2015. PMID: 25966434 Review.
-
Advances in targeted therapy of cholangiocarcinoma.Ann Med. 2024 Dec;56(1):2310196. doi: 10.1080/07853890.2024.2310196. Epub 2024 Feb 15. Ann Med. 2024. PMID: 38359439 Free PMC article. Review.
References
-
- Chen Y.-X., Zeng Z.-C., Tang Z.-Y., Fan J., Zhou J., Jiang W., Zeng M.-S., Tan Y.-S. Determining the Role of External Beam Radiotherapy in Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Analysis of 84 Patients. BMC Cancer. 2010;10:492. doi: 10.1186/1471-2407-10-492. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources